Home・Akcijų sąrašas・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Uždarymo kaina

13.78 -1.29

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

13.89

Max

14.13

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.4M -14M
Pelnas, tenkantis vienai akcijai	-0.15
Darbuotojai	37
EBITDA	312K -12M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+125.88% upside

Dividendai
By Acuity
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-161M 1.2B
Ankstesnė atidarymo kaina	15.07
Ankstesnė uždarymo kaina	13.78

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-22 23:56; UTC

AAR Corp shares are higher in after-market hours, reflecting earlier fluctuations. The stock remains below its 20-day moving average and near its one-month trading range.

2026-07-22 23:56; UTC

Correlated Moves

News

American Water Works Company Inc. is trading lower in after-market hours amid geopolitical tensions and rising crude oil prices impacting market sentiment.

2026-07-22 23:56; UTC

HCA Healthcare Inc shares are trading higher in after-market hours. Broader market sentiment is influenced by geopolitical tensions and rising crude oil prices.

2026-07-22 23:56; UTC

Correlated Moves

Lyft Inc shares are higher in after-market trading, showing a slight increase since Wednesday's close amid broader market dynamics and fluctuations in the ride-sharing sector.

2026-07-22 23:56; UTC

Correlated Moves

Costco Wholesale shares are lower in after-market hours amid ongoing geopolitical tensions and rising crude oil prices affecting market sentiment.

2026-07-22 23:56; UTC

ETF Constituents

The iShares Biotechnology ETF is trading higher in after-market hours, supported by gains from Medpace Holdings and other key holdings.

2026-07-22 23:56; UTC

Correlated Moves

Element Solutions Inc shares are higher in after-market trading, reflecting a modest gain. Similar trends were noted in correlated asset ITT Inc.

2026-07-22 23:56; UTC

Correlated Moves

Coeur Mining Inc shares are lower in after-market hours, reflecting a decline linked to a slight drop in silver prices.

2026-07-22 23:56; UTC

Badger Meter Inc shares are higher in after-market trading, recovering from earlier volatility without any specific news to explain the movement.

2026-07-22 23:56; UTC

Correlated Moves

Rambus Inc shares are higher in after-market trading, reflecting positive movement since Wednesday's close, alongside gains in MACOM Technology Solutions. Geopolitical tensions persist.

2026-07-22 23:56; UTC

Exelon shares are lower in after-market trading, reflecting stable performance within a one-month trading range. No specific news was identified.

2026-07-22 23:56; UTC

American Superconductor shares are lower in after-market trading, retracing from earlier gains and remaining below their 20-day moving average.

2026-07-22 23:56; UTC

NextDecade Corp. shares are lower in after-market hours amid geopolitical tensions and rising oil prices, reflecting routine fluctuations without specific company news.

2026-07-22 23:56; UTC

Comfort Systems USA Inc shares are lower in after-market trading, following a trend of higher closes. No specific news was identified for this movement.

2026-07-22 23:56; UTC

MasTec Inc. shares are modestly higher in after-market hours, with no specific company news identified. Broader market sentiment may be influenced by geopolitical tensions.

2026-07-22 23:56; UTC

Correlated Moves

Fortuna Silver Mines Inc. is trading lower in after-market hours, reflecting broader declines in the precious metals market amid ongoing geopolitical tensions.

2026-07-22 23:56; UTC

News

Wynn Resorts received approval to expand its Wynn Palace resort in Macau, including a new hotel and entertainment center. Shares showed little change in after-market trading.

2026-07-22 23:56; UTC

Intellia Therapeutics Inc shares are higher in after-market trading, though they remain below their 20-day moving average and near the lower end of their one-month range.

2026-07-22 23:56; UTC

ETF Constituents

iShares China Large-Cap ETF declines after market close, impacted by JD's negative return. The ETF remains above its 20-day moving average.

2026-07-22 23:56; UTC

Newmont Corporation shares are higher in after-market hours, reflecting a modest increase since Wednesday's close, with no specific news identified for the movement.

2026-07-22 23:56; UTC

Under Armour Inc shares are slightly higher in after-market hours, maintaining a position near the upper end of their one-month range.

2026-07-22 23:52; UTC

Lumentum Holdings Inc shares are higher in after-market trading, significantly above Wednesday's close and near the upper end of its one-month trading range.

2026-07-22 23:51; UTC

Blue Owl Capital Corp shares are higher in after-market trading. No specific news was identified to explain this movement amid cautious broader market sentiment.

2026-07-22 23:51; UTC

Upwork Inc. shares are lower during after-market hours amid broader market declines. Rising crude oil prices and geopolitical tensions are contributing to negative sentiment.

2026-07-22 23:51; UTC

MACOM Technology Solutions is higher in after-market trading, reflecting positive sentiment despite broader market concerns over rising crude oil prices and geopolitical tensions.

2026-07-22 23:51; UTC

Pinnacle West Capital Corp shares are lower in after-market trading, continuing weak sentiment from earlier. Broader market dynamics may be influencing cautious investor sentiment.

2026-07-22 23:51; UTC

HP Inc. shares are little changed in after-market trading. The broader market is lower amid rising crude oil prices and uncertainty over the Fed's interest rate decision.

2026-07-22 23:51; UTC

Ambarella Inc shares are higher in after-market trading, recovering from earlier fluctuations. Broader market sentiment remains cautious amid rising crude oil prices.

2026-07-22 23:51; UTC

Correlated Moves

Photronics Inc shares are higher in after-market trading, supported by a positive trend and correlations with MACOM Technology Solutions Holdings Inc.

2026-07-22 23:51; UTC

PDD Holdings Inc shares are higher in after-market trading, despite no specific news driving the price movement. The stock remains above its 20-day moving average.

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

125.88% į viršų

12 mėnesių prognozė

Vidutinis 31.6 USD 125.88%

Aukščiausias 40 USD

Žemiausias 27 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Corvus Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.